Results 111 to 120 of about 657,649 (153)

Case Report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up

Frontiers in Oncology
Breast secretory carcinoma (BSC) is a rare low-grade malignancy that frequently exhibits the ETV6::NTRK3 fusion gene and rarely presents with distant metastasis.
Fengbo Huang, Fengbo Huang, Jing Zhao, Jing Zhao, Jing Zhao, Jie Lian, Bo Hong, Xiaoyan Yu, Xiaojing Ma, Jiabin Lai, Wei Qian, Jinglian Tu, Fuming Qiu, Fuming Qiu, Fuming Qiu, Fuming Qiu, Hong Zou, Jian Huang, Jian Huang, Jian Huang, Jian Huang, Jinfan Li   +21 more
doaj   +1 more source

Five Trk Receptors in the Zebrafish

, 1995
Using a homology-based cloning strategy we have identified five members of the Trk family in the zebrafish Danio rerio. They are homologous to the three mammalian Trk receptors in their conserved intracellular kinase regions and the organization of their
Heinrich, Gerhard, Martin, Stella C., Marazzi, Giovanna, Sandell, Julie H.   +3 more
core   +1 more source

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

While NTRK fusion-positive cancers can be exquisitely sensitive to first-generation TRK inhibitors, resistance inevitably occurs, mediated in many cases by acquired NTRK mutations.
de Stanchina, Elisa, Toska, Eneda, Drilon, Alexander, Zhou, Chao, Harada, Guilherme, Roa, Paola, Repetto, Matteo, de Marchena, Michelle, Kong, Norman, Bardelli, Alberto, Foglizzo, Valentina, Bremer, Nicole Virginia, Yang, Soo-Ryum, Zhang, Bin, Liang, Ruixia, Ventura, Andrea, Kulick, Amanda, Cocco, Emiliano, Auwardt, Supipi, Sayed Ahmed, Shaza, Feng, Yangbo, Xu, Haipeng   +21 more
core   +1 more source

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion. [PDF]

J Adv Pract Oncol, 2020
Dunn DB.
europepmc   +1 more source

TRK inhibitors in pediatric gliomas. [PDF]

Neurooncol Adv
Perreault S, Doz F.
europepmc   +1 more source

Neoadjuvant TRK inhibitors versus chemotherapy in advanced NTRK fusion-positive sarcomas: a real-world evidence analysis. [PDF]

Oncologist
Zhu F, Cheng H, Han Y, Yang S, Zhu Z, Ren Q, Su Y, Wang Z, Qin H, Yang W, Wang S, Gao Y, Wang H.   +12 more
europepmc   +1 more source

TRK inhibitors in TRK fusion-positive cancers. [PDF]

Ann Oncol, 2019
Drilon A.
europepmc   +1 more source

The Research Progress of Neurotrophic Tyrosine Receptor Kinase <i>(NTRK)</i> Gene Fusions and Tropomyosin Receptor Kinase (<i>TRK</i>) Inhibitors: A Narrative Review. [PDF]

Iran J Public Health
Li J, Liang Y.
europepmc   +1 more source

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer. [PDF]

Med Chem Res
Lee S, Hu L.
europepmc   +1 more source

Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data. [PDF]

Endocr Relat Cancer
Waguespack SG, Brose MS, Lin JJ, McDermott R, Almubarak M, Bauman J, Casanova M, Kummar S, Lee SH, Rieke DT, Oh DY, Qi C, Neu N, Burcoveanu DI, Mussi CE, Drilon A, Hong DS, Cabanillas ME.   +17 more
europepmc   +1 more source